Moderate

HIV-2 infection (diagnosis & treatment essentials)

HIV-2 · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Second human retrovirus, endemic in West Africa and in people with West-African links. Slower CD4 decline, lower viral load, longer latency - but advanced disease and opportunistic infections are similar to HIV-1 (AIDS at CD4 <200). Crucially, HIV-2 is intrinsically resistant to NNRTIs, enfuvirtide and fostemsavir, which changes therapy.

Red flags

  • AIDS-defining illness / opportunistic infection
  • CD4 <200
  • Pregnancy
  • Virologic failure (low genetic barrier - as few as 2 NRTI mutations [Q151M + M184V] confer full resistance)
  • Dual HIV-1/HIV-2 infection

Assessment

Differential diagnosis

  • HIV-1 infection
  • Dual HIV-1/HIV-2 infection
  • Other causes of immunosuppression / AIDS-like illness

Investigations

  • HIV-1/2 differentiation immunoassay (Geenius HIV 1/2 Supplemental Assay or BioPlex 2200 HIV Ag-Ab)
  • Confirm with HIV-2-specific immunoblot/EIA or HIV-2 nucleic acid test (DNA/RNA)
  • CD4 count (AIDS if <200)
  • HIV-2 RNA viral load - limited availability (e.g. University of Washington; New York State DOH)
  • Suspect if HIV-1 Western blot indeterminate (gag+pol without env), or HIV-1 seropositive with low/undetectable VL, or virus non-genotypable on routine HIV-1 resistance testing

Management

  • Suspect in West-African origin/links with an AIDS-like illness/OI but HIV-1 seronegative, OR HIV-1 positive with undetectable VL and declining CD4
  • Confirm with differentiation assay + HIV-2 NAT
  • Do NOT use NNRTIs, enfuvirtide or fostemsavir (intrinsic resistance) - also in dual infection
  • Refer to HIV specialist for ART selection (not ED-initiated)
  • Screen for/treat OIs as per HIV-1 when CD4 <200
  • Manage dual HIV-1/HIV-2 infection with expert consultation (poor outcomes)

Drugs & doses

Preferred ART: 2 NRTIs (tenofovir-DF/FTC, tenofovir-AF/FTC, or abacavir/3TC) PLUS an integrase inhibitor (dolutegravir, bictegravir, raltegravir, or elvitegravir/cobicistat)
Alternative: 2 NRTIs + a boosted protease inhibitor (ritonavir- or cobicistat-boosted darunavir or lopinavir)
DO NOT use NNRTIs (efavirenz, rilpivirine, doravirine, etravirine), enfuvirtide, or fostemsavir - HIV-2 is intrinsically resistant
Avoid atazanavir (lower potency vs HIV-2); tenofovir/abacavir favoured over zidovudine
Test HLA-B*57:01 before abacavir (contraindicated if positive)
Per-drug mg doses not itemised in source - standard adult fixed-dose HIV-1 combinations apply

Disposition

Outpatient HIV specialist for ART initiation/selection; admit for AIDS-defining illness/OI. Therapy is not ED-initiated.

Complications & pitfalls

  • Opportunistic infections (TB, PCP, toxoplasmosis, cryptococcosis)
  • Rapid resistance/virologic failure on inadequate regimens
  • Mother-to-child transmission
  • Treatment failure in dual infection (high resistance rates)

Exam pearls

  • ED relevance = recognition + NOT starting an NNRTI-based regimen
  • HIV-2 RNA viral-load testing is limited and routine HIV-1 resistance assays will not genotype HIV-2
  • Endemic across West Africa (Senegal, Guinea-Bissau, Cote d'Ivoire, Nigeria, Ghana, etc.)
  • A single-tablet INSTI regimen (e.g. abacavir/3TC/dolutegravir or bictegravir/FTC/TAF) is preferred for adherence

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.